Drug intelligence / Profile preview

tranilast + fibrinogen + thrombin

Development stage: Unknown
Lead developer: Nuon Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

This is a combination of three components: tranilast (an antiallergic drug), fibrinogen (a coagulation factor), and thrombin (a serine protease). When fibrinogen and thrombin are combined, they form a fibrin sealant used to control bleeding during surgery when standard techniques are ineffective or impractical. Tranilast appears to inhibit the release of histamine from mast cells and has been shown to inhibit proliferation of fibroblasts. The combination may potentially enhance hemostatic effects while providing anti-inflammatory properties.

Targets

H (Histamine receptors)

Beyond the preview

Go deeper on tranilast + fibrinogen + thrombin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tranilast + fibrinogen + thrombin.

Explore the full profile